These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36892817)

  • 21. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet.
    Peng JH; Leng J; Tian HJ; Yang T; Fang Y; Feng Q; Zhao Y; Hu YY
    Front Pharmacol; 2018; 9():1399. PubMed ID: 30618733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.
    Li X; Du Y; Xue C; Kang X; Sun C; Peng H; Fang L; Han Y; Xu X; Zhao C
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease
    Zhu W; Zhou Y; Tsao R; Dong H; Zhang H
    Front Nutr; 2022; 9():861854. PubMed ID: 35662935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut Dysfunction and Non-alcoholic Fatty Liver Disease.
    Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H
    Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
    Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.
    Svegliati-Baroni G; Patrício B; Lioci G; Macedo MP; Gastaldelli A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
    Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
    Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.
    Poeta M; Pierri L; Vajro P
    Children (Basel); 2017 Aug; 4(8):. PubMed ID: 28767077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
    Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
    Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.